帕博利珠单抗单药治疗卡介苗无应答且无原位癌的高危非肌层浸润性膀胱癌(KEYNOTE-057):单臂、多中心、2期试验
KEYNOTE-057的B队列纳入132例卡介苗无应答、无原位癌的高危乳头状非肌层浸润性膀胱癌患者,接受帕博利珠单抗200 mg每3周一次最多35周期。12个月无病生存率为43.5%(95%CI 34.9-51.9),治疗相关不良事件发生率73%,3或4级治疗相关不良事件发生率14%,无治疗相关死亡。
要点
- 12个月无病生存率为43.5%(95%CI 34.9-51.9)。
- 治疗相关不良事件发生率73%,3或4级发生率14%。
- 无治疗相关死亡。
核心结论
- 帕博利珠单抗单药在卡介苗无应答、无原位癌的高危Ta或T1期膀胱癌中显示抗肿瘤活性且毒性可控,可能为拒绝或不适合根治性膀胱切除术的患者提供合适治疗选择,但需随机对照试验确认。
研究设计与样本
- KEYNOTE-057为单臂、2期研究,在14个国家54个中心开展。
- B队列纳入132例卡介苗无应答、无原位癌的高危乳头状非肌层浸润性膀胱癌患者,ECOG体能状态0-2,首次帕博利珠单抗给药前12周内需行经尿道膀胱肿瘤切除术。
- 患者接受帕博利珠单抗200 mg静脉注射每3周一次,最多35周期。
- 主要终点为12个月高危非肌层浸润性膀胱癌无病生存或进展性疾病,由膀胱镜、细胞学及中心病理和影像学审评评估。
主要发现
- 2016年4月12日至2021年6月17日入组132例患者,其中男性104例(79%)、女性28例(21%),既往卡介苗灌注中位10次(IQR 9-15)。
- 患者接受帕博利珠单抗中位10周期(IQR 6-27);截至2022年10月20日数据截止日,中位随访45.4个月(IQR 36.4-59.3),132例中5例(4%)仍在治疗。
- 12个月无病生存率为43.5%(95%CI 34.9-51.9)。
- 治疗相关不良事件发生于97/132例(73%),19例(14%)发生3或4级治疗相关不良事件,最常见为结肠炎3例(2%)和腹泻2例(2%)。
- 17/132例(13%)发生严重治疗相关不良事件,最常见为结肠炎3例(2%),无治疗相关死亡。
临床怎么用
- 作者认为,帕博利珠单抗单药可能为拒绝或不适合根治性膀胱切除术的卡介苗无应答、无原位癌的高危Ta或T1期膀胱癌患者提供治疗选择。
- 作者指出,研究结果需在随机对照试验中确认。
局限性
- 原文指出研究结果需在随机对照试验中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The KEYNOTE-057 trial evaluated activity and safety of pembrolizumab in patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer who were ineligible for or declined radical cystectomy. In cohort A (patients with carcinoma in situ, with or without papillary tumours) of the KEYNOTE-057 study, pembrolizumab monotherapy led to a complete response rate of 41% at 3 months, and 46% of responders maintained a response lasting at least 12 months. Here, we evaluate pembrolizumab monotherapy in cohort B of patients with papillary tumours without carcinoma in situ. METHODS: KEYNOTE-057 is a single-arm, phase 2 study in 54 sites (hospitals and cancer centres) in 14 countries. Cohort B eligible patients were aged 18 years and older, had an Eastern Cooperative Oncology Group performance status of 0-2, and had BCG-unresponsive high-risk non-muscle-invasive bladder cancer with papillary tumours (high-grade Ta or any-grade T1) without carcinoma in situ. Transurethral resection of bladder tumour within 12 weeks of first pembrolizumab dose was required. Patients received pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles. Primary endpoint was 12-month disease-free survival of high-risk non-muscle-invasive bladder cancer or progressive disease as assessed by cystoscopy, cytology, and central pathology and radiology review. Activity was assessed in all patients who received at least one dose of the study drug and had a baseline evaluation. Safety was assessed in all patients who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov number, NCT02625961, and is ongoing. FINDINGS: Between April 12, 2016, and June 17, 2021, 132 patients (104 [79%] men and 28 [21%] women) who had received a median of ten (IQR 9-15) previous BCG instillations were enrolled into cohort B of the study. Patients received a median of 10 cycles (IQR 6-27) of pembrolizumab. At data cutoff date, Oct 20, 2022, median follow-up was 45·4 months (IQR 36·4-59·3) and five (4%) of 132 patients remained on treatment. The 12-month disease-free survival was 43·5% (95% CI 34·9-51·9). Treatment-related adverse events occurred in 97 (73%) of 132 patients; 19 (14%) had a grade 3 or 4 treatment-related adverse event; the most common grade 3 or 4 treatment-related adverse events were colitis (in three [2%] patients) and diarrhoea (in two [2%]). 17 (13%) of 132 patients experienced serious treatment-related adverse events, of which colitis (three patients [2%]) was most common. No treatment-related deaths occurred. INTERPRETATION: Pembrolizumab monotherapy showed antitumour activity and manageable toxicity in patients with BCG-unresponsive high-risk Ta or T1 bladder cancer without carcinoma in situ and could potentially be a suitable treatment option for patients who decline or are ineligible for radical cystectomy. Findings will need to be confirmed in a randomised controlled trial. FUNDING: Merck Sharp & Dohme.
引用
- Necchi A, Roumiguié M, Kamat AM, et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024. PMID: 38740030. doi:10.1016/S1470-2045(24)00178-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。